His scientific interests lie mostly in Cancer research, Apoptosis, Pharmacology, In vivo and Navitoclax. His studies deal with areas such as Cell culture, Survivin, Immunology, Cell cycle and Regulation of gene expression as well as Cancer research. His Apoptosis study contributes to a more complete understanding of Biochemistry.
His In vivo research includes themes of Platelet and Paclitaxel. His work carried out in the field of Navitoclax brings together such families of science as Venetoclax, Survival analysis, Leukemia and Neutropenia. Saul H. Rosenberg has included themes like Oral administration and Obatoclax in his BH3 Mimetic ABT-737 study.
Saul H. Rosenberg mainly investigates Stereochemistry, Enzyme inhibitor, Cancer research, Biochemistry and Pharmacology. His Stereochemistry research is multidisciplinary, incorporating perspectives in Biological activity, Structure–activity relationship, Chemical synthesis and Enzyme. His studies in Cancer research integrate themes in fields like Cancer cell, Cancer, Cell culture, Apoptosis and Immunology.
His works in Programmed cell death and Bcl-2 family are all subjects of inquiry into Apoptosis. His Pharmacology research includes elements of Venetoclax and Navitoclax, In vivo. In his work, DNA repair is strongly intertwined with PARP inhibitor, which is a subfield of In vivo.
The scientist’s investigation covers issues in Cancer research, Pharmacology, Cancer, Cancer cell and Navitoclax. The various areas that Saul H. Rosenberg examines in his Cancer research study include Histone, Bromodomain, BRD4 and Leukemia, Immunology. The study incorporates disciplines such as Venetoclax, Blood flow and In vivo in addition to Pharmacology.
His In vivo research incorporates themes from Biochemistry, Nicotinamide, Adenosine triphosphate, Enzyme and NAD+ kinase. His Cancer cell study incorporates themes from Nicotinamide phosphoribosyltransferase, Carcinogenesis, Apoptosis, Programmed cell death and Enzyme activator. His biological study spans a wide range of topics, including Molecular biology and Multiple dosing.
Saul H. Rosenberg focuses on Navitoclax, Pharmacology, In vivo, Cell culture and Cancer. Stem cell, Cell growth, Carcinogenesis and Downregulation and upregulation is closely connected to Cancer cell in his research, which is encompassed under the umbrella topic of Navitoclax. In general Pharmacology, his work in Pharmacodynamics is often linked to Lymphocytopenia linking many areas of study.
His work in In vivo covers topics such as Apoptosis which are related to areas like Multiple dosing. His Cell culture study combines topics from a wide range of disciplines, such as Small molecule and Cell biology. As part of one scientific family, Saul H. Rosenberg deals mainly with the area of Cancer, narrowing it down to issues related to the Venetoclax, and often MCL1, Toxicity and Platelet.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf;Steven W. Elmore;Alexander R. Shoemaker;Robert C. Armstrong.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler.
Nature Medicine (2013)
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse;Alexander R. Shoemaker;Jessica Adickes;Mark G. Anderson.
Cancer Research (2008)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce.
Lancet Oncology (2010)
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.
Zhan Xiao;Zehan Chen;Angelo H. Gunasekera;Thomas J. Sowin.
Journal of Biological Chemistry (2003)
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.
Thorsten K Oost;Chaohong Sun;Robert C Armstrong;Ali-Samer Al-Assaad.
Journal of Medicinal Chemistry (2004)
Bcl-2 family proteins are essential for platelet survival
H Zhang;P M Nimmer;S K Tahir;J Chen.
Cell Death & Differentiation (2007)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson;Darren C. Phillips;Michael J. Mitten;Erwin R. Boghaert.
Science Translational Medicine (2015)
Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
Stephen K. Tahir;Xiufen Yang;Mark G. Anderson;Susan E. Morgan-Lappe.
Cancer Research (2007)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Loren M. Lasko;Clarissa G. Jakob;Rohinton P. Edalji;Wei Qiu.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: